Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
Kanal
Emanuel
E
Department of Radiology, University of Pittsburgh Medical Center-Presbyterian, 200 Lothrop St, Room D-132, Pittsburgh, PA 15213-2582, USA. ekanal@pitt.edu
Broome
Dale R
DR
Martin
Diego R
DR
Thomsen
Henrik S
HS
D003287:Contrast Media / Q000009:adverse effects*; D005355:Fibrosis / Q000139:chemically induced* / Q000453:epidemiology; D005682:Gadolinium; D019786:Gadolinium DTPA / Q000009:adverse effects*; D006571:Heterocyclic Compounds / Q000009:adverse effects*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008536:Meglumine / Q000009:adverse effects / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000150:complications*; D012306:Risk; D014481:United States; D014486:United States Food and Drug Administration
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; C064572:gadobenic acid; D008536:Meglumine; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA; C112666:gadoversetamide